/ /

  • linkedin
  • Increase Font
  • Sharebar

    Pain-preventing NSAID welcomed by patients and clinicians

    Multiple clinical studies demonstrate drug’s efficacy in cataract surgery

    A new 0.075% formulation of bromfenac ophthalmic solution (BromSite, Sun Pharma) could provide relief from pain and inflammation associated with cataract surgery, according to Sheri Rowen, MD, of Nvision Eye Centers, Newport Beach, CA.

    Last April, the FDA approved the nonsteroidal anti-inflammatory drug (NSAID) to prevent pain and treat inflammation associated with cataract surgery, Sun Pharma announced.

    Recent: European study with microstent demonstrates lowered IOP, use of fewer drugs

    “According to the study data, it has good aqueous concentrations of the molecule after 1 drop,” Dr. Rowen said. “So that is an encouraging sign.”

    Sun Pharma’s U.S. subsidiary, Sun Ophthalmics, began marketing BromSite in the United States last fall.

    The agent delivers bromfenac in a synthetic polymer of crosslinked polyacrylic acid developed as DuraSite by InSite Vision. DuraSite is also the vehicle for Bausch + Lomb’s besifloxacin ophthalmic suspension (Besivance) and Akorn’s azithromycin ophthalmic solution (AzaSite).

    Related: LENSAR files for bankruptcy with PDL BioPharma support

    DuraSite is mucoadhesive and “can be used to improve solubility, absorption, bioavailability and residence time as compared to conventional topical therapies,” according to Sun Pharma. Sun Pharma of Mumbai, India, purchased InSite Vision of Alameda, CA, in November 2015.

    The active ingredient is suspended in the DuraSite and is released in small doses each time the patient blinks, Dr. Rowen explained.

    More: Reviewing the year of cataract surgery advances

    The label calls for twice-daily dosing, morning and evening, beginning 1 day before surgery and ending 14 days after.

    Bromfenac, the active ingredient of BromSite, inhibits cyclooxygenase (cox) 1 and 2, enzymes responsible for forming prostaglandins.

    Phase III studies

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results